Vaxart Sale Purchase Of Stock from 2010 to 2025

VXRT Stock  USD 0.68  0.00  0.000001%   
Vaxart Sale Purchase Of Stock yearly trend continues to be comparatively stable with very little volatility. Sale Purchase Of Stock is likely to outpace its year average in 2025. From the period from 2010 to 2025, Vaxart Sale Purchase Of Stock quarterly data regression had r-value of  0.19 and coefficient of variation of  361.18. View All Fundamentals
 
Sale Purchase Of Stock  
First Reported
1992-03-31
Previous Quarter
-17 K
Current Value
494 K
Quarterly Volatility
20.9 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Vaxart financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vaxart's main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.1 M, Interest Expense of 1.4 M or Total Revenue of 6.3 M, as well as many indicators such as Price To Sales Ratio of 9.61, Dividend Yield of 0.0 or PTB Ratio of 2.34. Vaxart financial statements analysis is a perfect complement when working with Vaxart Valuation or Volatility modules.
  
Check out the analysis of Vaxart Correlation against competitors.

Latest Vaxart's Sale Purchase Of Stock Growth Pattern

Below is the plot of the Sale Purchase Of Stock of Vaxart Inc over the last few years. It is Vaxart's Sale Purchase Of Stock historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vaxart's overall financial position and show how it may be relating to other accounts over time.
Sale Purchase Of Stock10 Years Trend
Pretty Stable
   Sale Purchase Of Stock   
       Timeline  

Vaxart Sale Purchase Of Stock Regression Statistics

Arithmetic Mean10,371,515
Geometric Mean0.00
Coefficient Of Variation361.18
Mean Deviation20,929,742
Median24,000
Standard Deviation37,460,027
Sample Variance1403.3T
Range180.4M
R-Value0.19
Mean Square Error1447.4T
R-Squared0.04
Significance0.47
Slope1,519,943
Total Sum of Squares21048.8T

Vaxart Sale Purchase Of Stock History

2025-399.9 K
2024-420.9 K
2023-366 K
202217.5 M
20213.6 M
2020137.7 M
20192.5 M

About Vaxart Financial Statements

Vaxart shareholders use historical fundamental indicators, such as Sale Purchase Of Stock, to determine how well the company is positioned to perform in the future. Although Vaxart investors may analyze each financial statement separately, they are all interrelated. The changes in Vaxart's assets and liabilities, for example, are also reflected in the revenues and expenses on on Vaxart's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Sale Purchase Of Stock-420.9 K-399.9 K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Vaxart Stock Analysis

When running Vaxart's price analysis, check to measure Vaxart's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxart is operating at the current time. Most of Vaxart's value examination focuses on studying past and present price action to predict the probability of Vaxart's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxart's price. Additionally, you may evaluate how the addition of Vaxart to your portfolios can decrease your overall portfolio volatility.